LEVALBUTEROL TARTRATE - Generic Drug Details

What are the generic sources for levalbuterol tartrate and what is the scope of patent protection?

Levalbuterol tartrate is the generic ingredient in one branded drug marketed by Lupin and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Four suppliers are listed for this compound.

Summary for LEVALBUTEROL TARTRATE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	4
Clinical Trials:	5
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LEVALBUTEROL TARTRATE
What excipients (inactive ingredients) are in LEVALBUTEROL TARTRATE?	LEVALBUTEROL TARTRATE excipients list
DailyMed Link:	LEVALBUTEROL TARTRATE at DailyMed

Recent Clinical Trials for LEVALBUTEROL TARTRATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sunovion	Phase 2
Sunovion	Phase 3

See all LEVALBUTEROL TARTRATE clinical trials

Pharmacology for LEVALBUTEROL TARTRATE

Drug Class	beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists

Paragraph IV (Patent) Challenges for LEVALBUTEROL TARTRATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XOPENEX HFA	Inhalation Aerosol	levalbuterol tartrate	0.045 mg/actuation	021730	1	2012-02-27

US Patents and Regulatory Information for LEVALBUTEROL TARTRATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lupin	XOPENEX HFA	levalbuterol tartrate	AEROSOL, METERED;INHALATION	021730-001	Mar 11, 2005		RX	Yes	Yes

Expired US Patents for LEVALBUTEROL TARTRATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lupin	XOPENEX HFA	levalbuterol tartrate	AEROSOL, METERED;INHALATION	021730-001	Mar 11, 2005
Lupin	XOPENEX HFA	levalbuterol tartrate	AEROSOL, METERED;INHALATION	021730-001	Mar 11, 2005
Lupin	XOPENEX HFA	levalbuterol tartrate	AEROSOL, METERED;INHALATION	021730-001	Mar 11, 2005
Lupin	XOPENEX HFA	levalbuterol tartrate	AEROSOL, METERED;INHALATION	021730-001	Mar 11, 2005

Market Dynamics and Financial Trajectory for Levalbuterol Tartrate

Last updated: February 20, 2026

Levalbuterol tartrate is a selective β2-adrenergic receptor agonist indicated primarily for acute bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD). It is the active enantiomer of albuterol, offering potentially fewer side effects and increased efficacy.

Market Overview

The global respiratory drugs market, valued at approximately $26 billion in 2022, is expanding driven by rising prevalence of respiratory diseases. Levalbuterol tartrate constitutes a niche segment within this market, with sales driven by its use as a rescue inhaler and in hospital settings.

Key Market Players

• Sunovion Pharmaceuticals: Marketing XOPENEX (levalbuterol inhalation solution).
• Teva Pharmaceutical Industries: Produces generic formulations.
• Mylan (now part of Viatris): Offers generic levalbuterol products.
• Others: Smaller regional manufacturers and biotech firms exploring novel delivery systems.

Market Penetration and Adoption

Levalbuterol tartrate has growth potential in the following areas:

• Hospital and Emergency Use: Preferred for rapid relief of acute bronchospasm.
• Chronic Disease Management: Under consideration for maintenance therapy but limited by current guidelines.
• Generic Competition: High, exerting pressure on branded sales.

Regulatory and Patent Landscape

Patent Status

• Original patent rights for XOPENEX expired in 2014 in the U.S., opening the market for generics.
• No recent patents filed specifically for levalbuterol tartrate formulations, suggesting limited exclusivity periods.

Regulatory Pathway

• Approved by the FDA via New Drug Application (NDA) in the 1990s.
• Market authorization in Europe through the EMA, with ongoing approvals in various emerging markets.

Off-Label Use and Guidelines

• Recommended by the Global Initiative for Asthma (GINA) for acute symptom relief.
• Limited for chronic prophylaxis, constraining long-term market growth.

Market Dynamics

Drivers

• Increased prevalence of asthma (approx. 262 million globally in 2019) and COPD (over 200 million cases worldwide).
• Growing awareness of inhaler rescue medications.
• Evolution of inhalation device technology improving drug delivery efficiency.
• Shift toward selective β2-agonists with fewer cardiovascular side effects.

Challenges

• Widespread availability of generics, reducing profit margins.
• Competition from other inhalers including albuterol, salmeterol, and formoterol.
• Regulatory hurdles and approval delays in emerging markets.
• Potential for biosimilar and alternative therapies reducing demand.

Trends

• Developing advanced inhaler devices that improve dosing accuracy.
• Increasing adoption of combination inhalers that include levalbuterol with corticosteroids.
• Rising inclination toward customized therapies based on patient genetic profiles.

Financial Trajectory

Revenue Estimates

• Current Sales: Estimated at $300 million annually for the branded levalbuterol products globally.
• Growth Rate: Compound annual growth rate (CAGR) projected at 2.5% from 2023 to 2028, driven by wider accessibility and technological innovations.
• Generic Market Impact: Onset of generics in late 2010s caused a sharp decline in branded revenues by 20%-30%, with some markets witnessing more aggressive price erosion.

Cost and Profitability

• Manufacturing Costs: Low to moderate, leveraging existing inhaler production infrastructure.
• Pricing Strategies: Focused on healthcare provider bundling and insurance reimbursement channels.
• Margins: Branded formulations maintain gross margins around 50%, while generics margin is closer to 30%.

Investment and R&D Outlook

• Limited dedicated R&D for new formulations; focus shifts to device innovation.
• Larger firms examining combination therapies with levalbuterol for expanded indications.
• Emerging markets present opportunities with local manufacturing and registration.

Future Outlook

Levalbuterol tartrate's market is characterized by steady but slowing growth, primarily influenced by generic competition and regulatory environments. Innovations in inhaler delivery systems and combination therapies will determine near-term revenue prospects. While no significant patent protections remain, brands with strong distribution channels and device innovation could sustain profitability.

Key Takeaways

• Levalbuterol tartrate competes in a mature, highly commoditized market with limited premium pricing.
• Growth is constrained by widespread generic availability and competition from other bronchodilators.
• The drug's primary market remains acute care settings in developed regions.
• Emerging markets offer expansion opportunities with local manufacturing and regulatory approval.
• Investment focus should shift toward device innovation and combination inhalers to preserve margins.

FAQs

1. What is the primary therapeutic use of levalbuterol tartrate?
It treats acute bronchospasm in asthma and COPD patients as a fast-acting rescue inhaler.

2. How does levalbuterol differ from albuterol?
Levalbuterol is the pure (S)-enantiomer of albuterol, with potentially fewer side effects and increased potency.

3. What are the main competitors in the market?
Generic formulations from Teva and Mylan, and other inhalers containing albuterol, salmeterol, or formoterol.

4. How will generic pressure impact future revenues?
Generics will likely erode profit margins, making branded sales increasingly challenging without device or formulation differentiation.

5. Are there ongoing R&D efforts for levalbuterol?
Most efforts focus on inhaler device technology and combination therapies, with limited development of new formulations.

---

References

1. Global Initiative for Asthma. (2022). GINA Report, Global Strategy for Asthma Management and Prevention.
2. IQVIA. (2022). Pharmaceutical Market Data.
3. Food and Drug Administration. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations.
4. European Medicines Agency. (2022). Assessment reports for respiratory medications.
5. MarketsandMarkets. (2022). Inhalation Drugs Market by Product, Application, & Region.